12 Month Price Forecast For FENC
Distance to FENC Price Forecasts
FENC Price Momentum
🤔 Considering Fennec (FENC)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: January 23, 2025 6:48 AM UTC
FENC Analyst Ratings & Price Targets
Based on our analysis of 7 Wall Street analysts, FENC has a consensus that is bullish. The median price target is $13.00, with forecasts ranging from $10.00 to $15.00. Currently, there are 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
With FENC currently trading at $5.73, the median price forecast suggests a 126.9% upside. The most optimistic forecast comes from Chase Knickerbocker at Craig-Hallum, projecting a 161.8% upside, while at provides the most conservative target, suggesting a 74.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
FENC Analyst Consensus
FENC Price Target Range
Latest FENC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for FENC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 17, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $13.00 |
| Aug 22, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $13.00 |
| Aug 14, 2024 | Craig-Hallum | Chase Knickerbocker | Buy | Maintains | $15.00 |
| May 15, 2024 | Craig-Hallum | Chase Knickerbocker | Buy | Maintains | $17.00 |
| May 15, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $15.00 |
| Apr 4, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $18.00 |
| Mar 18, 2024 | Craig-Hallum | Chase Knickerbocker | Buy | Maintains | $18.00 |
| Aug 4, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $17.00 |
| Jun 21, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $18.00 |
| Apr 6, 2023 | Cantor Fitzgerald | Charles Robertson II | Overweight | Maintains | $16.00 |
| Apr 4, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $18.00 |
| Mar 31, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $18.00 |
| Jan 26, 2023 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $18.00 |
| Nov 22, 2022 | Cantor Fitzgerald | Charles Duncan | Overweight | Upgrade | $12.00 |
| Oct 20, 2022 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $18.00 |
| Sep 26, 2022 | Wedbush | David Nierengarten | Outperform | Maintains | $19.00 |
| Sep 7, 2022 | Capital One | Naureen Quibria | Overweight | Initiates | $11.00 |
| Aug 8, 2022 | Craig-Hallum | Chase Knickerbocker | Buy | Assumes | $14.00 |
| Jun 3, 2021 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $14.00 |
| Apr 21, 2021 | Craig-Hallum | Buy | Initiates | $0.00 |
Stocks Similar to Fennec Pharmaceuticals Inc
The following stocks are similar to Fennec based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Fennec Pharmaceuticals Inc (FENC) Financial Data
Fennec Pharmaceuticals Inc has a market capitalization of $172.40M with a P/E ratio of 60.4x. The company generates $49.35M in trailing twelve-month revenue with a -2.3% profit margin.
Revenue growth is +7.0% quarter-over-quarter, while maintaining an operating margin of -74.6% and return on equity of +138.1%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Fennec Pharmaceuticals Inc (FENC) Company Overview
About Fennec Pharmaceuticals Inc
Develops treatments for pediatric cancer patients.
The company focuses on developing and commercializing biopharmaceutical products, specifically targeting pediatric oncology. It generates revenue through the sale of its product candidate, PEDMARK, which is aimed at preventing ototoxicity associated with platinum-based chemotherapy. Sales are facilitated through regional pediatric oncology specialists and medical science liaisons.
Fennec Pharmaceuticals, previously known as Adherex Technologies, was incorporated in 1996 and is headquartered in Research Triangle Park, North Carolina. The company's focus on a niche market positions it strategically within the biopharmaceutical sector, addressing critical needs in pediatric healthcare.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
29
CEO
Mr. Rostislav Raykov
Country
United States
IPO Year
2017
Website
www.fennecpharma.comFennec Pharmaceuticals Inc (FENC) Latest News & Analysis
Fennec Pharmaceuticals has repaid $13 million of its $32 million convertible debt, reducing annual interest expenses by $1.5 million and alleviating potential equity overhang of 1.6 million shares.
Fennec Pharmaceuticals' $13 million debt repayment reduces interest expenses and mitigates equity overhang, potentially enhancing financial stability and shareholder value.
PEDMARQSI® is now the sole treatment approved by NHS England and Wales for preventing cisplatin-induced ototoxicity in children and young people aged 1 month to 17 years.
PEDMARQSI's unique status as the sole treatment for a significant side effect of cisplatin positions it for strong market demand, potentially boosting revenue for its manufacturer.
Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX:FRX) will participate in the H.C. Wainwright Fireside Chat on December 16, 2024, at 11:00 a.m. ET.
Fennec Pharmaceuticals' participation in the H.C. Wainwright Fireside Chat could signal upcoming developments or insights, potentially affecting stock performance and investor sentiment.
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) will hold its Q3 2024 Earnings Conference Call on November 9, 2024, at 8:30 AM ET, featuring CFO Robert Andrade and CEO Jeff Hackman.
Fennec Pharmaceuticals' Q3 earnings call may reveal financial performance and strategic updates, influencing stock valuation and investor sentiment on growth potential.
Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
2 months agoIn Q3 2024, the company reported net product sales of $7.0 million, driven by AYA segment growth. They have $40 million in cash to fund operations through at least 2026.
Strong Q3 sales and successful reimbursement strategies indicate growth potential. Leadership changes may enhance strategic direction, while ample cash reserves ensure operational stability.
Adherex Technologies Inc. (FENC) reported a quarterly loss of $0.21 per share, exceeding the Zacks Consensus Estimate of $0.13 and worsening from a loss of $0.07 per share a year earlier.
Adherex's larger-than-expected quarterly loss signals worsening financial health, potentially impacting investor confidence and stock performance.
Frequently Asked Questions About FENC Stock
What is Fennec Pharmaceuticals Inc's (FENC) stock forecast for 2025?
Based on our analysis of 7 Wall Street analysts, Fennec Pharmaceuticals Inc (FENC) has a median price target of $13.00. The highest price target is $15.00 and the lowest is $10.00.
Is FENC stock a good investment in 2025?
According to current analyst ratings, FENC has 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $5.73. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for FENC stock?
Wall Street analysts predict FENC stock could reach $13.00 in the next 12 months. This represents a 126.9% increase from the current price of $5.73. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Fennec Pharmaceuticals Inc's business model?
The company focuses on developing and commercializing biopharmaceutical products, specifically targeting pediatric oncology. It generates revenue through the sale of its product candidate, PEDMARK, which is aimed at preventing ototoxicity associated with platinum-based chemotherapy. Sales are facilitated through regional pediatric oncology specialists and medical science liaisons.
What is the highest forecasted price for FENC Fennec Pharmaceuticals Inc?
The highest price target for FENC is $15.00 from Chase Knickerbocker at Craig-Hallum, which represents a 161.8% increase from the current price of $5.73.
What is the lowest forecasted price for FENC Fennec Pharmaceuticals Inc?
The lowest price target for FENC is $10.00 from at , which represents a 74.5% increase from the current price of $5.73.
What is the overall FENC consensus from analysts for Fennec Pharmaceuticals Inc?
The overall analyst consensus for FENC is bullish. Out of 7 Wall Street analysts, 5 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $13.00.
How accurate are FENC stock price projections?
Stock price projections, including those for Fennec Pharmaceuticals Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
